• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom more than doubles profits on 25% sales growth in Q2

July 28, 2023 By Sean Whooley

Dexcom updated logoDexcom (Nasdaq:DXCM) shares are up today on second-quarter results that topped the consensus forecast.

Shares of DXCM rose 2.3% at $132.35 apiece after the market closed yesterday. By the next afternoon, DXCM shares were up more than 4% to $134.71 apiece.  MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up slightly.

The San Diego-based continuous glucose monitor (CGM) maker posted profits of $115.9 million. That equals 28¢ per share on sales of $871.3 million for the three months ended June 30, 2023.

Dexcom more than doubled its profits on sales growth of 25.2%.

Adjusted to exclude one-time items, earnings per share came in at 34¢, 11¢ ahead of expectations on Wall Street. Sales also topped the analysts’ forecast of $841.6 million.

How Dexcom upped revenues and doubled profits

Dexcom attributed the significant revenue growth to volume growth in conjunction with strong new customer additions. The company said this continues to serve as a primary growth driver as the awareness of real-time CGM increases. Dexcom also launched its next-generation G7 CGM in the U.S. just before the quarter began. Midway through the quarter, a new Medicare guideline increased the addressable market for the company’s CGMs, too.

BTIG analysts Marie Thibault and Sam Eiber say “robust” G7 adoption drove growth in the quarter. The majority of G7 users are new to Dexcom, they said, and there are already 8,000 physicians in the U.S. who are new to Dexcom prescribing G7.

During the quarter, Dexcom also announced a plan to bring new glucose sensor to the market for people who don’t use insulin. Chief Commercial Officer Teri Lawver outlined this plan in a recent interview with Drug Delivery Business News.

“In the second quarter, we advanced several key strategic initiatives and shared our latest vision for the future of Dexcom at our 2023 Investor Day,” said Kevin Sayer, Dexcom chair, president and CEO. “Given our strong start to the year and rapidly growing market opportunity, we are pleased to raise our 2023 revenue and margin guidance.”

Dexcom now expects revenues to land between $3.5 billion and $3.55 billion for 2023. That marks 20%-22% growth and an increase from previous guidance for between $3.4 billion and $3.515 billion. The company projects a non-GAAP gross profit margin of about 63% and an adjusted EBITDA margin of approximately 26.5%.

The analysts’ view

Thibault and Eiber wrote that Dexcom believes it’s winning the market share in nearly all major reimbursed countries. Success with the U.S. basal-only population — helped by the Medicare decision — drove increased guidance, they said.

The analysts reiterated their “Buy” rating.

There were big expectations for Dexcom heading into this Q2 print and the company delivered, topping consensus sales estimates by $30M and raising the full-year outlook well above the beat,” the analysts wrote. “This was a fairly flawless quarter and we think shares of DXCM can move higher on Friday despite being priced for near-perfection.”

William Blair analyst Margaret Kaczor highlighted Dexcom’s significant momentum as proven by the quarterly results. She also believes the non-insulin sensor could prove a “catalyst for adoption” moving forward.

“While the strength internationally stands out as a strong indicator of momentum abroad, the guidance raise was a surprise and makes us more encouraged in the traction the company is seeing in the G7 launch (several positive metrics referenced on the call, particularly around share gains) and basal adoption (the impact to revenues was raised relative to prior guidance though was not quantified this quarter),” Kaczor wrote.

This story originally ran on July 27, 2023. Update July 28 with the next-day stock price. 

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Technology, Wall Street Beat Tagged With: Dexcom

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS